Tuhura Biosciences, Inc. (HURA) - 10-K Summary
Business Context and Reporting Period
Company: Tuhura Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Tuhura is a clinical-stage immuno-oncology company developing novel therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company operates three distinct technology platforms: the Immune Fx (IFx) innate immune agonist platform, the VISTA-inhibiting antibody TBS-2025 (acquired via merger), and Delta Opioid Receptor (DOR) antibody-drug conjugates (ADCs).
Key Developments in 2025:
- Kineta Merger: Completed the acquisition of Kineta, Inc. on June 30, 2025, acquiring rights to TBS-2025.
- IFx-2.0 Phase 3: Initiated a single randomized, placebo-controlled Phase 3 registration trial in June 2025 for IFx-2.0 as an adjunctive therapy to Keytruda in first-line treatment for advanced/metastatic Merkel cell carcinoma.
- Capital Raises: Completed a private placement in June 2025 (approx. $12.6M gross) and a registered direct offering in December 2025 (approx. $15.6M gross across three closings).
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Revenue | $0.0 | $0.0 |
| Net Loss | $(30.1) | $(21.7) |
| Operating Expenses | $31.8 | $17.6 |
| Research & Development | $20.5 | $13.3 |
| General & Administrative | $7.6 | $3.9 |
| Acquisition-Related Costs | $3.7 | $0.4 |
| Cash & Cash Equivalents (Year End) | $3.6 | $12.7 |
| Accumulated Deficit | $(141.2) | $(111.1) |
| Net Cash Used in Operating Activities | $(27.6) | $(14.7) |
Note: The company has no revenue from product sales. All financial figures are in USD millions unless otherwise noted.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $8.4 million (38.6%) year-over-year, driven primarily by higher R&D expenses and significant acquisition-related costs associated with the Kineta merger.
- R&D Expense Growth: R&D expenses rose by $7.2 million, reflecting ongoing clinical development of IFx-2.0, the initiation of TBS-2025 development, and increased personnel/facility costs.
- Acquisition Costs: Acquisition-related costs surged to $3.7 million in 2025 compared to $0.4 million in 2024, directly tied to the Kineta transaction.
- Balance Sheet Impact: Cash and cash equivalents decreased by approximately $9.0 million due to operating burn and investing activities, despite financing inflows of roughly $20.0 million. The company recognized $11.3 million in In-Process Research and Development (IPR&D) and $10.7 million in Goodwill from the Kineta acquisition.
Guidance, Outlook, and Risks
Outlook and Liquidity:
- Going Concern: The company has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and the need for additional financing. The independent auditor included an explanatory paragraph regarding this uncertainty.
- Cash Runway: Management believes existing cash ($3.6M) plus proceeds from the December 2025 offering ($7.0M received in Q1 2026) will fund operations through the early third quarter of 2026.
- Future Funding: The company anticipates needing substantial additional capital to advance clinical trials and commercialization efforts. It plans to raise funds through equity offerings, debt, or collaborations.
Key Risks and Contingencies:
- Clinical Trial Risk: Success depends on the Phase 3 trial for IFx-2.0 and future trials for TBS-2025. Failure to meet endpoints or delays could materially impair the business.
- Regulatory Risk: The company relies on FDA accelerated approval pathways; regulatory requirements are unpredictable and may change.
- Legal Proceedings: In December 2025, the company filed a lawsuit in Delaware Court of Chancery against VGXI, Inc. and GeneOne Life Sciences, Inc., alleging breach of contract and fraud regarding the failure to produce GMP-grade plasmid DNA for clinical trials.
- Stock Price Volatility: The company received a Nasdaq notification in January 2026 regarding non-compliance with minimum bid price requirements (stock closed below $1.00 for 30 days), though it regained compliance in February 2026.
Investor Verification Checklist
- Cash Runway Validation: Verify the exact timing of the $7.0M proceeds from the second and third closings of the December 2025 Registered Direct Offering to confirm the "early Q3 2026" liquidity estimate.
- Legal Action Status: Monitor the status of the lawsuit against VGXI and GeneOne regarding GMP-grade plasmid DNA supply, as this could impact the Phase 3 trial timeline.
- Phase 3 Enrollment: Track enrollment progress for the IFx-2.0 Phase 3 trial in Merkel cell carcinoma, which is critical for the company's primary value proposition.
- Capital Requirements: Assess the company's ability to raise additional capital in the current market environment given the "substantial doubt" going concern warning.
- IPR&D Valuation: Review the valuation methodology for the $11.3M IPR&D asset acquired from Kineta, as this is a significant intangible asset on the balance sheet.